

Carlo Salvarani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/203805/publications.pdf>

Version: 2024-02-01

530
papers

32,593
citations

5896

81
h-index

6131

159
g-index

539
all docs

539
docs citations

539
times ranked

17745
citing authors

#	ARTICLE	IF	CITATIONS
1	Polymyalgia Rheumatica and Giant-Cell Arteritis. <i>New England Journal of Medicine</i> , 2002, 347, 261-271.	27.0	1,002
2	The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 338-347.	2.4	977
3	Trial of Tocilizumab in Giant-Cell Arteritis. <i>New England Journal of Medicine</i> , 2017, 377, 317-328.	27.0	974
4	EULAR recommendations for the management of primary small and medium vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 310-317.	0.9	889
5	Tocilizumab in patients with severe COVID-19: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e474-e484.	3.9	772
6	EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 636-643.	0.9	753
7	Polymyalgia rheumatica and giant-cell arteritis. <i>Lancet</i> , The, 2008, 372, 234-245.	13.7	674
8	2018 Update of the EULAR recommendations for the management of large vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 19-30.	0.9	667
9	EULAR recommendations for the management of Behçet disease. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 1656-1662.	0.9	624
10	Retroperitoneal fibrosis. <i>Lancet</i> , The, 2006, 367, 241-251.	13.7	612
11	EULAR recommendations for the management of large vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 318-323.	0.9	596
12	Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia. <i>JAMA Internal Medicine</i> , 2021, 181, 24.	5.1	593
13	Primary central nervous system vasculitis: analysis of 101 patients. <i>Annals of Neurology</i> , 2007, 62, 442-451.	5.3	543
14	Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis. <i>Annals of Internal Medicine</i> , 2007, 146, 621.	3.9	491
15	2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 484-492.	0.9	451
16	2018 update of the EULAR recommendations for the management of Behçet's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2018-213225.	0.9	442
17	The Incidence of Giant Cell Arteritis in Olmsted County, Minnesota: Apparent Fluctuations in a Cyclic Pattern. <i>Annals of Internal Medicine</i> , 1995, 123, 192.	3.9	291
18	Takayasu's arteritis: A study of 104 Italian patients. <i>Arthritis and Rheumatism</i> , 2005, 53, 100-107.	6.7	273

#	ARTICLE	IF	CITATIONS
19	2012 Provisional classification criteria for polymyalgia rheumatica: A European League Against Rheumatism/American College of Rheumatology collaborative initiative. <i>Arthritis and Rheumatism</i> , 2012, 64, 943-954.	6.7	273
20	Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 1594-1600.	0.9	267
21	Giant cell arteritis with low erythrocyte sedimentation rate: Frequency of occurrence in a population-based study. <i>Arthritis and Rheumatism</i> , 2001, 45, 140-145.	6.7	254
22	Adult primary central nervous system vasculitis. <i>Lancet, The</i> , 2012, 380, 767-777.	13.7	247
23	Large-vessel giant cell arteritis: a cohort study. <i>Rheumatology</i> , 2015, 54, 463-470.	1.9	245
24	Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. <i>Arthritis and Rheumatism</i> , 2004, 51, 264-268.	6.7	241
25	Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. <i>Arthritis and Rheumatism</i> , 1997, 40, 1873-1878.	6.7	222
26	Role of imaging studies in the diagnosis and follow-up of large-vessel vasculitis: an update. <i>Rheumatology</i> , 2007, 47, 403-408.	1.9	221
27	2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1799-1807.	0.9	220
28	Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2005, 53, 293-297.	6.7	218
29	Treatment of longstanding active giant cell arteritis with infliximab: Report of four cases. <i>Arthritis and Rheumatism</i> , 2001, 44, 2933-2935.	6.7	207
30	Prednisone plus Methotrexate for Polymyalgia Rheumatica. <i>Annals of Internal Medicine</i> , 2004, 141, 493.	3.9	204
31	Tocilizumab: a novel therapy for patients with large-vessel vasculitis. <i>Rheumatology</i> , 2012, 51, 151-156.	1.9	203
32	Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. <i>Arthritis and Rheumatism</i> , 1991, 34, 351-356.	6.7	198
33	Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. <i>Lancet, The</i> , 2011, 378, 338-346.	13.7	189
34	Clinical features of polymyalgia rheumatica and giant cell arteritis. <i>Nature Reviews Rheumatology</i> , 2012, 8, 509-521.	8.0	185
35	The impact of 18F-FDG PET on the management of patients with suspected large vessel vasculitis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 344-353.	6.4	182
36	Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: A prospective follow-up study. <i>Seminars in Arthritis and Rheumatism</i> , 2000, 30, 17-24.	3.4	178

#	ARTICLE	IF	CITATIONS
37	Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients. <i>Journal of Autoimmunity</i> , 2015, 62, 67-74.	6.5	178
38	Epidemiology of polymyalgia rheumatica in olmsted county, minnesota, 1970-1991. <i>Arthritis and Rheumatism</i> , 1995, 38, 369-373.	6.7	175
39	Biopsy Findings in Primary Angiitis of the Central Nervous System. <i>American Journal of Surgical Pathology</i> , 2009, 33, 35-43.	3.7	170
40	Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: An approach to a personalized medicine. <i>Arthritis Care and Research</i> , 2013, 65, 94-100.	3.4	170
41	Is Duplex Ultrasonography Useful for the Diagnosis of Giant-Cell Arteritis?. <i>Annals of Internal Medicine</i> , 2002, 137, 232.	3.9	169
42	Management of Behcet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behcet disease. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1528-1534.	0.9	166
43	Giant Cell Arteritis and Polymyalgia Rheumatica. , 2009, , 285-304.		166
44	A α 2-related angiitis. <i>Neurology</i> , 2013, 81, 1596-1603.	1.1	163
45	Infliximab plus Prednisone or Placebo plus Prednisone for the Initial Treatment of Polymyalgia Rheumatica. <i>Annals of Internal Medicine</i> , 2007, 146, 631.	3.9	158
46	Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study. <i>Rheumatology</i> , 2007, 46, 1161-1164.	1.9	153
47	Giant cell arteritis: Involvement of intracranial arteries. <i>Arthritis and Rheumatism</i> , 2006, 55, 985-989.	6.7	147
48	Inflamed Temporal Artery. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1360-1370.	3.7	147
49	2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2015, 67, 2569-2580.	5.6	146
50	Musculoskeletal Manifestations in a Population-based Cohort of Inflammatory Bowel Disease Patients. <i>Scandinavian Journal of Gastroenterology</i> , 2001, 36, 1307-1313.	1.5	144
51	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. <i>American Journal of Human Genetics</i> , 2015, 96, 565-580.	6.2	144
52	Distal musculoskeletal manifestations in polymyalgia rheumatica: A prospective followup study. <i>Arthritis and Rheumatism</i> , 1998, 41, 1221-1226.	6.7	141
53	EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1744-1750.	0.9	139
54	Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: A prospective followup study. <i>Arthritis and Rheumatism</i> , 2005, 53, 33-38.	6.7	136

#	ARTICLE	IF	CITATIONS
55	Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis. <i>Rheumatology</i> , 2008, 48, 250-253.	1.9	134
56	An Update of the Mayo Clinic Cohort of Patients With Adult Primary Central Nervous System Vasculitis. <i>Medicine (United States)</i> , 2015, 94, e738.	1.0	133
57	Are polymyalgia rheumatica and giant cell arteritis the same disease?. <i>Seminars in Arthritis and Rheumatism</i> , 2004, 33, 294-301.	3.4	130
58	Primary central nervous system vasculitis: pathology and mechanisms. <i>Acta Neuropathologica</i> , 2012, 123, 759-772.	7.7	130
59	Identification of multiple independent susceptibility loci in the HLA region in Behçet's disease. <i>Nature Genetics</i> , 2013, 45, 319-324.	21.4	130
60	Positron emission tomography (PET): Evaluation of chronic periaortitis. <i>Arthritis and Rheumatism</i> , 2005, 53, 298-303.	6.7	128
61	Infliximab for the treatment of Neuro-Behçet's disease: A case series and review of the literature. <i>Arthritis and Rheumatism</i> , 2008, 59, 285-290.	6.7	127
62	Distal extremity swelling with pitting edema in polymyalgia rheumatica. Report of nineteen cases. <i>Arthritis and Rheumatism</i> , 1996, 39, 73-80.	6.7	122
63	Visual loss and other cranial ischaemic complications in giant cell arteritis. <i>Nature Reviews Rheumatology</i> , 2017, 13, 476-484.	8.0	121
64	Proximal Bursitis in Active Polymyalgia Rheumatica. <i>Annals of Internal Medicine</i> , 1997, 127, 27.	3.9	120
65	Primary CNS vasculitis with spinal cord involvement. <i>Neurology</i> , 2008, 70, 2394-2400.	1.1	118
66	Adult Primary Central Nervous System Vasculitis Treatment and Course: Analysis of One Hundred Sixty-Three Patients. <i>Arthritis and Rheumatology</i> , 2015, 67, 1637-1645.	5.6	118
67	Remitting seronegative symmetrical synovitis with pitting oedema (RS3PE) syndrome: a prospective follow up and magnetic resonance imaging study. <i>Annals of the Rheumatic Diseases</i> , 1999, 58, 230-236.	0.9	113
68	Successful treatment of SAPHO syndrome with infliximab: report of two cases. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 375-376.	0.9	112
69	Primary central nervous system vasculitis: comparison of patients with and without cerebral amyloid angiopathy. <i>Rheumatology</i> , 2008, 47, 1671-1677.	1.9	111
70	Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica. Quantitative analysis and influence of corticosteroid treatment. <i>Arthritis and Rheumatism</i> , 1996, 39, 1199-1207.	6.7	107
71	Clinical features and epidemiology of spondyloarthritis associated with inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , 2009, 15, 2449.	3.3	107
72	International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. <i>Arthritis and Rheumatism</i> , 2009, 61, 1235-1242.	6.7	104

#	ARTICLE	IF	CITATIONS
73	Chronic periaortitis and HLA-DRB1*03: Another clue to an autoimmune origin. <i>Arthritis and Rheumatism</i> , 2006, 55, 126-130.	6.7	102
74	Patient Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA and OMERACT Study. <i>Journal of Rheumatology</i> , 2011, 38, 898-903.	2.0	101
75	Shoulder ultrasonography in the diagnosis of polymyalgia rheumatica: a case-control study. <i>Journal of Rheumatology</i> , 2001, 28, 1049-55.	2.0	101
76	Epidemiology and clinical course of Behçet's disease in the Reggio Emilia area of Northern Italy: A seventeen-year population-based study. <i>Arthritis and Rheumatism</i> , 2007, 57, 171-178.	6.7	100
77	The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain. <i>Journal of Rheumatology</i> , 2000, 27, 2179-84.	2.0	96
78	Angiography-Negative Primary Central Nervous System Vasculitis. <i>Medicine (United States)</i> , 2008, 87, 264-271.	1.0	95
79	Rehabilitation Interventions for Post-Acute COVID-19 Syndrome: A Systematic Review. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 5185.	2.6	95
80	Identification of the Clinical Features Distinguishing Psoriatic Arthritis and Fibromyalgia. <i>Journal of Rheumatology</i> , 2012, 39, 849-855.	2.0	94
81	Behçet's disease and cardiovascular involvement. <i>Lupus</i> , 2005, 14, 723-726.	1.6	93
82	Uveitis and Other Ocular Complications Following COVID-19 Vaccination. <i>Journal of Clinical Medicine</i> , 2021, 10, 5960.	2.4	92
83	Primary central nervous system vasculitis with prominent leptomeningeal enhancement: A subset with a benign outcome. <i>Arthritis and Rheumatism</i> , 2008, 58, 595-603.	6.7	91
84	Management of major organ involvement of Behçet's syndrome: a systematic review for update of the EULAR recommendations. <i>Rheumatology</i> , 2018, 57, 2200-2212.	1.9	89
85	Cervical interspinous bursitis in active polymyalgia rheumatica. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 758-761.	0.9	88
86	Imaging Findings of Cerebral Amyloid Angiopathy, A β -Related Angiitis (ABRA), and Cerebral Amyloid Angiopathy-Related Inflammation. <i>Medicine (United States)</i> , 2016, 95, e3613.	1.0	86
87	Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease. <i>Autoimmunity Reviews</i> , 2014, 13, 822-830.	5.8	84
88	Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study. <i>Clinical Rheumatology</i> , 2017, 36, 183-189.	2.2	84
89	Definition of remission and relapse in polymyalgia rheumatica: data from a literature search compared with a Delphi-based expert consensus. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 447-453.	0.9	81
90	Performance of the new 2012 EULAR/ACR classification criteria for polymyalgia rheumatica: comparison with the previous criteria in a single-centre study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1190-1193.	0.9	81

#	ARTICLE	IF	CITATIONS
91	Polymyalgia rheumatica. Best Practice and Research in Clinical Rheumatology, 2004, 18, 705-722.	3.3	80
92	The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. Rheumatology, 2008, 47, 1664-1670.	1.9	80
93	Primary systemic amyloidosis presenting as giant cell arteritis and polymyalgia rheumatica. Arthritis and Rheumatism, 1994, 37, 1621-1626.	6.7	79
94	New approaches in the treatment of Adamantiades-Behçet's disease. Current Opinion in Rheumatology, 2006, 18, 3-9.	4.3	79
95	Flares in Biopsy-Proven Giant Cell Arteritis in Northern Italy. Medicine (United States), 2016, 95, e3524.	1.0	78
96	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. American Journal of Human Genetics, 2017, 100, 64-74.	6.2	78
97	Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. Lancet, The, 2020, 396, 267-276.	13.7	78
98	Prevalence of psoriatic arthritis in Italian psoriatic patients. Journal of Rheumatology, 1995, 22, 1499-503.	2.0	78
99	Tocilizumab for severe refractory neuro-Behçet: Three cases IL-6 blockade in neuro-Behçet. Seminars in Arthritis and Rheumatism, 2015, 44, 472-475.	3.4	75
100	Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study. Internal Medicine Journal, 2020, 50, 1085-1090.	0.8	75
101	Retroperitoneal Fibrosis: Evolving Concepts. Rheumatic Disease Clinics of North America, 2007, 33, 803-817.	1.9	74
102	Glucocorticoid Dosages and Acuteâ€Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab. Arthritis and Rheumatology, 2019, 71, 1329-1338.	5.6	74
103	Chronic periaortitis: a large-vessel vasculitis?. Current Opinion in Rheumatology, 2011, 23, 1-6.	4.3	73
104	Musculoskeletal manifestations in a population-based cohort of patients with giant cell arteritis. Arthritis and Rheumatism, 1999, 42, 1259-1266.	6.7	72
105	Large-vessel involvement in recent-onset giant cell arteritis: a case-control colour-Doppler sonography study. Rheumatology, 2012, 51, 730-734.	1.9	72
106	Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. Rheumatology, 2008, 47, 872-876.	1.9	71
107	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis. Arthritis and Rheumatology, 2022, 74, 393-399.	5.6	71
108	The cervical spine in patients with psoriatic arthritis: a clinical, radiological and immunogenetic study.. Annals of the Rheumatic Diseases, 1992, 51, 73-77.	0.9	70

#	ARTICLE	IF	CITATIONS
109	Small vessel vasculitis surrounding an uninfamed temporal artery and isolated vasa vasorum vasculitis of the temporal artery: Two subsets of giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 549-556.	6.7	69
110	The Role of Tumour Necrosis Factor in the Pathogenesis of Immune-Mediated Diseases. <i>International Journal of Immunopathology and Pharmacology</i> , 2014, 27, 1-10.	2.1	69
111	Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows. <i>Journal of Clinical Medicine</i> , 2020, 9, 1082.	2.4	68
112	Tuberculous uveitis, a resurgent and underdiagnosed disease. <i>International Ophthalmology</i> , 2009, 29, 67-74.	1.4	67
113	Validation of the classification criteria for cryoglobulinaemic vasculitis. <i>Rheumatology</i> , 2014, 53, 2209-2213.	1.9	67
114	Ectopic expression of CXCL13, BAFF, APRIL and LT- α^2 is associated with artery tertiary lymphoid organs in giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 235-243.	0.9	67
115	Difference in the expression of IL-9 and IL-17 correlates with different histological pattern of vascular wall injury in giant cell arteritis. <i>Rheumatology</i> , 2015, 54, 1596-1604.	1.9	66
116	The Sex Influence on Response to Tumor Necrosis Factor- α Inhibitors and Remission in Axial Spondyloarthritis. <i>Journal of Rheumatology</i> , 2018, 45, 195-201.	2.0	66
117	Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy. <i>Clinical and Experimental Rheumatology</i> , 1987, 5, 205-15.	0.8	66
118	Inflammatory changes of hip synovial structures in polymyalgia rheumatica. <i>Clinical and Experimental Rheumatology</i> , 2005, 23, 462-8.	0.8	66
119	Seronegative spondyloarthritides. <i>Best Practice and Research in Clinical Rheumatology</i> , 2002, 16, 723-739.	3.3	65
120	Fast spin echo-T2-weighted sequences with fat saturation in dactylitis of spondylarthritis. <i>Arthritis and Rheumatism</i> , 2002, 46, 2964-2967.	6.7	65
121	^{18}F -fluorodeoxyglucose positron emission tomography in the diagnosis and followup of idiopathic retroperitoneal fibrosis. <i>Arthritis and Rheumatism</i> , 2005, 53, 122-125.	6.7	65
122	Adalimumab in the Treatment of Immune-Mediated Diseases. <i>International Journal of Immunopathology and Pharmacology</i> , 2014, 27, 33-48.	2.1	65
123	Polymyalgia rheumatica. <i>Lancet</i> , The, 1997, 350, 43-47.	13.7	64
124	Patient-reported Outcomes in Polymyalgia Rheumatica. <i>Journal of Rheumatology</i> , 2012, 39, 795-803.	2.0	64
125	Nailfold capillaroscopic changes in dermatomyositis and polymyositis. <i>Clinical Rheumatology</i> , 2015, 34, 279-284.	2.2	64
126	Imaging of vasculitis: State of the art. <i>Best Practice and Research in Clinical Rheumatology</i> , 2016, 30, 688-706.	3.3	64

#	ARTICLE	IF	CITATIONS
127	Contrast-enhanced Ultrasound of the Carotid Artery in Patients With Large Vessel Vasculitis: Correlation With Positron Emission Tomography Findings. <i>Arthritis Care and Research</i> , 2017, 69, 143-149.	3.4	64
128	Newly diagnosed vs. relapsing giant cell arteritis: Baseline data from the GiACTA trial. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 657-664.	3.4	62
129	Vascular endothelial growth factor gene polymorphisms in Behçet's disease. <i>Journal of Rheumatology</i> , 2004, 31, 1785-9.	2.0	62
130	The causes of uveitis in a referral centre of Northern Italy. <i>International Ophthalmology</i> , 2010, 30, 521-529.	1.4	61
131	Primary central nervous system vasculitis presenting with intracranial hemorrhage. <i>Arthritis and Rheumatism</i> , 2011, 63, 3598-3606.	6.7	61
132	Laboratory investigations useful in giant cell arteritis and Takayasu's arteritis. <i>Clinical and Experimental Rheumatology</i> , 2003, 21, S23-8.	0.8	61
133	Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey. <i>Journal of Rheumatology</i> , 2008, 35, 270-7.	2.0	61
134	Remission in ankylosing spondylitis treated with anti-TNF- α drugs: a national multicentre study. <i>Rheumatology</i> , 2013, 52, 1914-1919.	1.9	60
135	RS3PE syndrome: an overview. <i>Clinical and Experimental Rheumatology</i> , 2000, 18, S53-5.	0.8	60
136	Efficacy of infliximab in resistant psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2003, 49, 541-545.	6.7	59
137	Tocilizumab for polymyalgia rheumatica: Report of two cases and review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 43, 113-118.	3.4	59
138	Efficacy of tocilizumab in Takayasu arteritis: Multicenter retrospective study of 46 patients. <i>Journal of Autoimmunity</i> , 2018, 91, 55-60.	6.5	59
139	Efficacy of tumor necrosis factor α blockade in primary central nervous system vasculitis resistant to immunosuppressive treatment. <i>Arthritis and Rheumatism</i> , 2008, 59, 291-296.	6.7	58
140	Is colour duplex sonography-guided temporal artery biopsy useful in the diagnosis of giant cell arteritis? A randomized study. <i>Rheumatology</i> , 2015, 54, 400-404.	1.9	58
141	Ultrasonographic and Clinical Assessment of Peripheral Entesitis in Patients with Psoriatic Arthritis, Psoriasis, and Fibromyalgia Syndrome: The ULISSE Study. <i>Journal of Rheumatology</i> , 2019, 46, 904-911.	2.0	58
142	Relationship between interleukin 6 promoter polymorphism at position -174, IL-6 serum levels, and the risk of relapse/recurrence in polymyalgia rheumatica. <i>Journal of Rheumatology</i> , 2006, 33, 703-8.	2.0	58
143	Management of skin, mucosa and joint involvement of Behçet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behçet's syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 752-762.	3.4	56
144	Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis. <i>RMD Open</i> , 2019, 5, e001020.	3.8	56

#	ARTICLE	IF	CITATIONS
145	Longitudinal examination with shoulder ultrasound of patients with polymyalgia rheumatica. <i>Rheumatology</i> , 2009, 48, 1566-1569.	1.9	55
146	IL-33 is overexpressed in the inflamed arteries of patients with giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 258-264.	0.9	55
147	Incidence, Prevalence, and Survival of Biopsy-Proven Giant Cell Arteritis in Northern Italy During a 26-Year Period. <i>Arthritis Care and Research</i> , 2017, 69, 430-438.	3.4	55
148	Localized vasculitis of the gastrointestinal tract: a case series. <i>Rheumatology</i> , 2010, 49, 1326-1335.	1.9	54
149	Aortitis and periaortitis in ankylosing spondylitis. <i>Joint Bone Spine</i> , 2011, 78, 451-455.	1.6	54
150	Treatment of refractory polymyalgia rheumatica with etanercept: An open pilot study. <i>Arthritis and Rheumatism</i> , 2007, 57, 1514-1519.	6.7	52
151	Adult primary central nervous system vasculitis. <i>Current Opinion in Rheumatology</i> , 2012, 24, 46-52.	4.3	52
152	Analysis of the common genetic component of large-vessel vasculitides through a meta-immunochip strategy. <i>Scientific Reports</i> , 2017, 7, 43953.	3.3	52
153	Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. <i>RMD Open</i> , 2019, 5, e001003.	3.8	52
154	Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial. <i>Lancet Rheumatology</i> , The, 2021, 3, e328-e336.	3.9	52
155	Retroperitoneal fibrosis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2012, 26, 439-448.	3.3	51
156	Brief Report: Interleukin-6 as an Inflammatory Mediator and Target of Therapy in Chronic Periaortitis. <i>Arthritis and Rheumatism</i> , 2013, 65, 2469-2475.	6.7	51
157	New insights into the pathogenesis of giant cell arteritis. <i>Autoimmunity Reviews</i> , 2017, 16, 675-683.	5.8	51
158	Rapidly progressive primary central nervous system vasculitis. <i>Rheumatology</i> , 2011, 50, 349-358.	1.9	50
159	Anti-TNF Agents as Therapeutic Choice in Immune-Mediated Inflammatory Diseases: Focus on Adalimumab. <i>International Journal of Immunopathology and Pharmacology</i> , 2014, 27, 11-32.	2.1	50
160	Rituximab therapy for Takayasu arteritis: a seven patients experience and a review of the literature. <i>Rheumatology</i> , 2018, 57, 1151-1155.	1.9	50
161	Intercellular adhesion molecule 1 gene polymorphisms in polymyalgia rheumatica/giant cell arteritis: association with disease risk and severity. <i>Journal of Rheumatology</i> , 2000, 27, 1215-21.	2.0	50
162	Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study. <i>Journal of Rheumatology</i> , 2003, 30, 760-3.	2.0	50

#	ARTICLE	IF	CITATIONS
163	Vascular endothelial growth factor gene polymorphisms in giant cell arteritis. <i>Journal of Rheumatology</i> , 2003, 30, 2160-4.	2.0	50
164	Susceptibility and severity of COVID-19 in patients treated with bDMARDs and tsDMARDs: a population-based study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 986.2-988.	0.9	49
165	Efficacy and safety of mavrimumab in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 653-661.	0.9	49
166	Comparison between colour duplex sonography findings and different histological patterns of temporal artery. <i>Rheumatology</i> , 2013, 52, 2268-2274.	1.9	48
167	Inflamed shoulder structures in polymyalgia rheumatica with normal erythrocyte sedimentation rate. <i>Arthritis and Rheumatism</i> , 2001, 44, 1155-1159.	6.7	47
168	Psoriatic Arthritis Spondylitis Radiology Index: A Modified Index for Radiologic Assessment of Axial Involvement in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2009, 36, 1006-1011.	2.0	47
169	Etanercept in the Longterm Treatment of Patients With Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2009, 36, 1256-1264.	2.0	47
170	Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation. <i>Critical Care</i> , 2020, 24, 589.	5.8	47
171	Ankylosing spondylitis and undifferentiated spondyloarthropathies: a clinical review and description of a disease subset with older age at onset. <i>Current Opinion in Rheumatology</i> , 2001, 13, 280-284.	4.3	46
172	Post-treatment residual tissue in idiopathic retroperitoneal fibrosis: active residual disease or silent "scar" ? A study using 18F-fluorodeoxyglucose positron emission tomography. <i>Clinical and Experimental Rheumatology</i> , 2005, 23, 231-4.	0.8	46
173	Detection of parvovirus B19 DNA by polymerase chain reaction in giant cell arteritis: A case-control study. <i>Arthritis and Rheumatism</i> , 2002, 46, 3099-3101.	6.7	45
174	Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: a prospective study and review of the literature. <i>Journal of Thoracic Disease</i> , 2019, 11, 1621-1628.	1.4	45
175	Diagnostic accuracy of a velcro sound detector (VECTOR) for interstitial lung disease in rheumatoid arthritis patients: the InSPIRAtE validation study (INterStitial pneumonia in rheumatoid ArThritis with) Tj ETQq1 1 0z84314 rgBT /Ove		
176	HLA-DRB1 alleles associated with polymyalgia rheumatica in northern Italy: correlation with disease severity. <i>Annals of the Rheumatic Diseases</i> , 1999, 58, 303-308.	0.9	44
177	Switching from infliximab to onceâ€‘weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: Results of a fiftyâ€‘fourâ€‘week study. <i>Arthritis and Rheumatism</i> , 2006, 55, 812-816.	6.7	44
178	NKG₂D stimulated T-cell autoreactivity in giant cell arteritis and polymyalgia rheumatica. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1852-1859.	0.9	44
179	Treatment of primary CNS vasculitis with rituximab: Case report. <i>Neurology</i> , 2014, 82, 1287-1288.	1.1	44
180	Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies. <i>Autoimmunity Reviews</i> , 2019, 18, 164-176.	5.8	44

#	ARTICLE	IF	CITATIONS
181	Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 277.	2.4	44
182	Isolated peripheral enthesitis and/or dactylitis: a subset of psoriatic arthritis. <i>Journal of Rheumatology</i> , 1997, 24, 1106-10.	2.0	42
183	Interleukin-10 promoter polymorphisms in giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 4011-4017.	6.7	40
184	Late onset undifferentiated spondyloarthritis presenting with polymyalgia rheumatica features: description of seven cases. <i>Rheumatology International</i> , 2007, 27, 927-933.	3.0	40
185	Aortic dilatation in patients with large vessel vasculitis: A longitudinal case control study using PET/CT. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 1074-1082.	3.4	40
186	Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 407.	2.4	40
187	Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor- α therapy: Is there a need for more comprehensive screening procedures?. <i>Arthritis and Rheumatism</i> , 2009, 61, 801-812.	6.7	39
188	A putative functional variant within the <i>UBAC2</i> gene is associated with increased risk of Behçet's disease. <i>Arthritis and Rheumatism</i> , 2011, 63, 3607-3612.	6.7	39
189	Low dose cyclosporine A in psoriatic arthritis: relation between soluble interleukin 2 receptors and response to therapy. <i>Journal of Rheumatology</i> , 1992, 19, 74-9.	2.0	39
190	Endothelial nitric oxide synthase gene polymorphisms in Behçet's disease. <i>Journal of Rheumatology</i> , 2002, 29, 535-40.	2.0	39
191	The right place of interleukin-1 inhibitors in the treatment of Behçet's syndrome: a systematic review. <i>Rheumatology International</i> , 2019, 39, 971-990.	3.0	38
192	Resolution of vascular inflammation in patients with new-onset giant cell arteritis: data from the RIGA study. <i>Rheumatology</i> , 2021, 60, 3851-3861.	1.9	38
193	Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study. <i>Rheumatology</i> , 2010, 49, 1107-1111.	1.9	37
194	Remission in Nonradiographic Axial Spondyloarthritis Treated with Anti-tumor Necrosis Factor- α Drugs: An Italian Multicenter Study. <i>Journal of Rheumatology</i> , 2015, 42, 258-263.	2.0	37
195	MicroRNA markers of inflammation and remodelling in temporal arteries from patients with giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1527-1533.	0.9	37
196	Association of MICA alleles and HLA-B51 in Italian patients with Behçet's disease. <i>Journal of Rheumatology</i> , 2001, 28, 1867-70.	2.0	37
197	Influence of the <i>IL17A</i> locus in giant cell arteritis susceptibility. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1742-1745.	0.9	36
198	Cytokine Profiling in Aqueous Humor Samples From Patients With Non-Infectious Uveitis Associated With Systemic Inflammatory Diseases. <i>Frontiers in Immunology</i> , 2020, 11, 358.	4.8	36

#	ARTICLE	IF	CITATIONS
199	Remitting distal extremity swelling with pitting edema: a distinct syndrome or a clinical feature of different inflammatory rheumatic diseases?. <i>Journal of Rheumatology</i> , 1997, 24, 249-52.	2.0	36
200	Therapy with cyclosporine in psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 1997, 27, 36-43.	3.4	35
201	Endothelial nitric oxide synthase gene polymorphisms in giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2003, 48, 3219-3223.	6.7	35
202	No detection of varicella-zoster virus in temporal arteries of patients with giant cell arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 235-240.	3.4	35
203	Is PET/CT essential in the diagnosis and follow-up of temporal arteritis?. <i>Autoimmunity Reviews</i> , 2017, 16, 1125-1130.	5.8	35
204	Diagnosis and Treatment of Giant Cell Arteritis. <i>Drugs and Aging</i> , 2008, 25, 281-297.	2.7	34
205	Improving therapeutic options for patients with giant cell arteritis. <i>Current Opinion in Rheumatology</i> , 2008, 20, 17-22.	4.3	34
206	Differential effects of anti-TNF- α drugs on fibroblast-like synoviocyte apoptosis. <i>Rheumatology</i> , 2010, 49, 480-489.	1.9	34
207	Canakinumab in a case of Adult onset Still's disease: Efficacy only on systemic manifestations. <i>Joint Bone Spine</i> , 2014, 81, 376-377.	1.6	34
208	2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1160-1166.	0.9	34
209	Interstitial pneumonia with autoimmune features: A single center prospective follow-up study. <i>Autoimmunity Reviews</i> , 2020, 19, 102451.	5.8	34
210	Polymyalgia rheumatica: a disorder of extraarticular synovial structures?. <i>Journal of Rheumatology</i> , 1999, 26, 517-21.	2.0	34
211	Long-term follow-up of polymyalgia rheumatica patients treated with methotrexate and steroids. <i>Clinical and Experimental Rheumatology</i> , 2008, 26, 395-400.	0.8	34
212	Correlations between histopathological findings and clinical manifestations in biopsy-proven giant cell arteritis. <i>Journal of Autoimmunity</i> , 2016, 69, 94-101.	6.5	33
213	Clinical Spectrum of Medium-Sized Vessel Vasculitis. <i>Arthritis Care and Research</i> , 2017, 69, 884-891.	3.4	33
214	Vascular endothelial growth factor production in polymyalgia rheumatica. <i>Arthritis and Rheumatism</i> , 2000, 43, 2472-2480.	6.7	32
215	Chronic periaortitis with thoracic aorta and epiaortic artery involvement: a systemic large vessel vasculitis?. <i>Rheumatology</i> , 2015, 54, 2004-2009.	1.9	32
216	The Sex Influence on Response to Tumor Necrosis Factor- α Inhibitors and Remission in Axial Spondyloarthritis. <i>Journal of Rheumatology</i> , 2018, 45, 195-201.	2.0	32

#	ARTICLE	IF	CITATIONS
217	Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study. <i>RMD Open</i> , 2021, 7, e001519.	3.8	32
218	Incidence of Stroke in Young Adults in the Reggio Emilia Area, Northern Italy. <i>Neuroepidemiology</i> , 1993, 12, 82-87.	2.3	31
219	Expression of interleukin-32 in the inflamed arteries of patients with giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2011, 63, 2097-2104.	6.7	31
220	IL-23A, IL-23R, IL-17A and IL-17R polymorphisms in different psoriatic arthritis clinical manifestations in the northern Italian population. <i>Rheumatology International</i> , 2013, 33, 1165-1176.	3.0	31
221	Update on polymyalgia rheumatica. <i>European Journal of Internal Medicine</i> , 2013, 24, 583-589.	2.2	31
222	Lung complications of Sjogren syndrome. <i>European Respiratory Review</i> , 2020, 29, 200021.	7.1	31
223	Epidemiology of granulomatosis with polyangiitis (Wegener's granulomatosis) in Northern Italy: A 15-year population-based study. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 202-207.	3.4	30
224	Mycophenolate mofetil in primary central nervous system vasculitis. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 55-59.	3.4	30
225	Paraneoplastic remitting seronegative symmetrical synovitis with pitting edema. <i>Clinical and Experimental Rheumatology</i> , 1999, 17, 741-4.	0.8	30
226	Clinical manifestations of Behçet's disease in 137 Italian patients: results of a multicenter study. <i>Clinical and Experimental Rheumatology</i> , 2004, 22, S46-51.	0.8	30
227	The role of infectious agents in the pathogenesis of vasculitis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2008, 22, 897-911.	3.3	29
228	Standard and biological treatment in large vessel vasculitis: guidelines and current approaches. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 345-360.	3.0	29
229	Relapses and long-term remission in large vessel giant cell arteritis in northern Italy: Characteristics and predictors in a long-term follow-up study. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 549-558.	3.4	29
230	Long-term remission, relapses and maintenance therapy in adult primary central nervous system vasculitis: A single-center 35-year experience. <i>Autoimmunity Reviews</i> , 2020, 19, 102497.	5.8	29
231	Polymyalgia manifestations in different conditions mimicking polymyalgia rheumatica. <i>Clinical and Experimental Rheumatology</i> , 2000, 18, 755-9.	0.8	29
232	Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 1995, 54, 640-644.	0.9	28
233	Psoriatic arthritis. <i>Current Opinion in Rheumatology</i> , 1998, 10, 299-305.	4.3	28
234	Acute exacerbation of interstitial lung disease associated with rheumatic disease. <i>Nature Reviews Rheumatology</i> , 2022, 18, 85-96.	8.0	28

#	ARTICLE	IF	CITATIONS
235	Corticosteroid injections in polymyalgia rheumatica: a double-blind, prospective, randomized, placebo controlled study. <i>Journal of Rheumatology</i> , 2000, 27, 1470-6.	2.0	28
236	¹⁸ F-Fluorodeoxyglucose-positron emission tomography: A new explorative perspective. <i>Experimental Gerontology</i> , 2003, 38, 463-470.	2.8	27
237	Anti-TNF- α Drugs Differently Affect the TNF α -sTNFR System and Monocyte Subsets in Patients with Psoriasis. <i>PLoS ONE</i> , 2016, 11, e0167757.	2.5	27
238	Management of primary and secondary central nervous system vasculitis. <i>Current Opinion in Rheumatology</i> , 2016, 28, 21-28.	4.3	27
239	Long-term remission in biopsy proven giant cell arteritis: A retrospective cohort study. <i>Journal of Autoimmunity</i> , 2017, 77, 39-44.	6.5	27
240	Red flags for appropriate referral to the gastroenterologist and the rheumatologist of patients with inflammatory bowel disease and spondyloarthritis. <i>Clinical and Experimental Immunology</i> , 2019, 196, 123-138.	2.6	27
241	Heritable and non-heritable uncommon causes of stroke. <i>Journal of Neurology</i> , 2021, 268, 2780-2807.	3.6	27
242	Remitting distal lower extremity swelling with pitting oedema in acute sarcoidosis. <i>Annals of the Rheumatic Diseases</i> , 1997, 56, 565-566.	0.9	26
243	Role of imaging in vasculitis and connective tissue diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2008, 22, 1075-1091.	3.3	26
244	Histopathologic Findings of Patients With Biopsy-Negative Giant Cell Arteritis Compared to Those Without Arteritis: A Population-Based Study. <i>Arthritis Care and Research</i> , 2016, 68, 865-870.	3.4	26
245	Survival predictors in biopsy-proven giant cell arteritis: a northern Italian population-based study. <i>Rheumatology</i> , 2019, 58, 609-616.	1.9	26
246	Efficacy and safety of TNF- α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients. <i>Rheumatology</i> , 2022, 61, 1376-1384.	1.9	26
247	The impact of chest CT body composition parameters on clinical outcomes in COVID-19 patients. <i>PLoS ONE</i> , 2021, 16, e0251768.	2.5	26
248	Diagnostic approach in a patient presenting with polymyalgia. <i>Clinical and Experimental Rheumatology</i> , 1999, 17, 276-8.	0.8	26
249	Are steroids alone sufficient for the treatment of giant cell arteritis?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 277-292.	3.3	25
250	Idiopathic aortitis: an underrecognized vasculitis. <i>Arthritis Research and Therapy</i> , 2011, 13, 119.	3.5	25
251	CC chemokine receptor 5 polymorphism in chronic periaortitis. <i>Rheumatology</i> , 2011, 50, 1025-1032.	1.9	25
252	“Disease knowledge index” and perspectives on reproductive issues: A nationwide study on 398 women with autoimmune rheumatic diseases. <i>Joint Bone Spine</i> , 2019, 86, 475-481.	1.6	25

#	ARTICLE	IF	CITATIONS
253	Adrenal gland hypofunction in active polymyalgia rheumatica. effect of glucocorticoid treatment on adrenal hormones and interleukin 6. <i>Journal of Rheumatology</i> , 2002, 29, 748-56.	2.0	25
254	Soluble Receptor Activator of Nuclear Factor- κ B Ligand (sRANKL)/Osteoprotegerin Balance in Ageing and Age-Associated Diseases. <i>Biogerontology</i> , 2004, 5, 119-127.	3.9	24
255	Psoriatic disease: concepts and implications. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 627-630.	2.4	24
256	Vasculitis of the Gastrointestinal Tract in Chronic Periaortitis. <i>Medicine (United States)</i> , 2011, 90, 28-39.	1.0	24
257	Role of Imaging in the Diagnosis of Large and Medium-Sized Vessel Vasculitis. <i>Rheumatic Disease Clinics of North America</i> , 2013, 39, 593-608.	1.9	24
258	New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. <i>Rheumatology</i> , 2022, 61, 2915-2922.	1.9	24
259	Distal extremity swelling with pitting edema in psoriatic arthritis: a case-control study. <i>Clinical and Experimental Rheumatology</i> , 2001, 19, 291-6.	0.8	24
260	Fat suppression magnetic resonance imaging in shoulders of patients with polymyalgia rheumatica. <i>Journal of Rheumatology</i> , 2004, 31, 120-4.	2.0	24
261	Tumor necrosis factor-alpha protects synovial cells from nitric oxide induced apoptosis through phosphoinositide 3-kinase Akt signal transduction. <i>Journal of Rheumatology</i> , 2006, 33, 1061-8.	2.0	24
262	Cortisol, Dehydroepiandrosterone Sulfate, and Androstenedione Levels in Patients with Polymyalgia Rheumatica during Twelve Months of Glucocorticoid Therapy. <i>Annals of the New York Academy of Sciences</i> , 2002, 966, 91-96.	3.8	23
263	Peripheral inflammatory arthritis in patients with chronic periaortitis: report of five cases and review of the literature. <i>Rheumatology</i> , 2007, 47, 315-318.	1.9	23
264	Serum interleukin-6 receptor in polymyalgia rheumatica: A potential marker of relapse/recurrence risk. <i>Arthritis and Rheumatism</i> , 2008, 59, 1147-1154.	6.7	23
265	Wegener Granulomatosis with Spleen Infarction: Case Report and Review of the Literature. <i>Seminars in Arthritis and Rheumatism</i> , 2008, 37, 328-333.	3.4	23
266	Is the nail psoriasis severity index reliable in the assessment of nail psoriasis by rheumatologists?. <i>Arthritis Care and Research</i> , 2012, 64, 455-458.	3.4	23
267	Evidence of association of the <i>NLRP1</i> gene with giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 628-630.	0.9	23
268	Tocilizumab for the treatment of giant cell arteritis. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 339-349.	3.0	23
269	Large Vessel Dilatation in Giant Cell Arteritis: A Different Subset of Disease?. <i>Arthritis Care and Research</i> , 2018, 70, 1406-1411.	3.4	23
270	Autologous Fat Grafting for the Oral and Digital Complications of Systemic Sclerosis: Results of a Prospective Study. <i>Aesthetic Plastic Surgery</i> , 2020, 44, 1820-1832.	0.9	23

#	ARTICLE	IF	CITATIONS
271	Interleukin-6 promoter polymorphism at position -174 in giant cell arteritis. <i>Journal of Rheumatology</i> , 2005, 32, 2173-7.	2.0	23
272	Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, S7-14.	0.8	23
273	LYMPHOCYTE SUBPOPULATIONS ANALYSIS IN PERIPHERAL BLOOD IN POLYMYALGIA RHEUMATICA/GLANT CELL ARTERITIS. <i>Rheumatology</i> , 1993, 32, 666-670.	1.9	22
274	The relationship between serum-soluble interleukin-2 receptor and radiological evolution in psoriatic arthritis patients treated with cyclosporin-A. <i>Rheumatology International</i> , 1998, 18, 27-33.	3.0	22
275	Pericarditis heralding Erdheim-Chester Disease. <i>Circulation</i> , 2008, 118, e511-2.	1.6	22
276	Primary central nervous system vasculitis associated with lymphoma. <i>Neurology</i> , 2018, 90, e847-e855.	1.1	22
277	Human Dental Pulp Stem Cells Modulate Cytokine Production in vitro by Peripheral Blood Mononuclear Cells From Coronavirus Disease 2019 Patients. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 609204.	3.7	22
278	Significance of inflammation restricted to adventitial/periadventitial tissue on temporal artery biopsy. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1064-1072.	3.4	22
279	Efficacy of infliximab in a patient with refractory idiopathic retroperitoneal fibrosis. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, 776-8.	0.8	22
280	The role of PET/CT in disease activity assessment in patients with large vessel vasculitis. <i>Rheumatology</i> , 2022, 61, 4809-4816.	1.9	22
281	Fast spin echo-T2-weighted sequences with fat saturation in toe dactylitis of spondyloarthritis. <i>Clinical Rheumatology</i> , 2008, 27, 1141-1145.	2.2	21
282	Searching for viral antibodies and genome in intraocular fluids of patients with Fuchs uveitis and non-infectious uveitis. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2013, 251, 1607-1612.	1.9	21
283	Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register. <i>Joint Bone Spine</i> , 2014, 81, 508-512.	1.6	21
284	Unmet Needs in the Pathogenesis and Treatment of Vasculitides. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 54, 244-260.	6.5	21
285	Symptomatic psoriatic dactylitis is associated with ultrasound determined extra-synovial inflammatory features and shorter disease duration. <i>Clinical Rheumatology</i> , 2019, 38, 903-911.	2.2	21
286	Tofacitinib for the Treatment of Severe Interstitial Lung Disease Related to Rheumatoid Arthritis. <i>Case Reports in Medicine</i> , 2021, 2021, 1-5.	0.7	21
287	Genetic Association of a Gain-of-Function <i>IFNGR1</i> Polymorphism and the Intergenic Region <i>LNCAROD/DKK1</i> With Behçet's Disease. <i>Arthritis and Rheumatology</i> , 2021, 73, 1244-1252.	5.6	21
288	Role of PD-L1 in licensing immunoregulatory function of dental pulp mesenchymal stem cells. <i>Stem Cell Research and Therapy</i> , 2021, 12, 598.	5.5	21

#	ARTICLE	IF	CITATIONS
289	Polymyalgia rheumatica. <i>Lancet</i> , 1996, 348, 550-551.	13.7	20
290	CD8 LYMPHOCYTE SUBSETS IN ACTIVE POLYMYALGIA RHEUMATICA: COMPARISON WITH ELDERLY-ONSET AND ADULT RHEUMATOID ARTHRITIS AND INFLUENCE OF PREDNISONE THERAPY. <i>Rheumatology</i> , 1996, 35, 642-648.	1.9	20
291	Renal cell carcinoma mimicking polymyalgia rheumatica. <i>Scandinavian Journal of Rheumatology</i> , 2002, 31, 103-103.	1.1	20
292	Angiotensin II protects fibroblast-like synoviocytes from apoptosis via the AT1-NF- κ B pathway. <i>Rheumatology</i> , 2007, 46, 1252-1257.	1.9	20
293	Increased expression of interleukin-22 in patients with giant cell arteritis. <i>Rheumatology</i> , 2018, 57, 64-72.	1.9	20
294	Primary central nervous system vasculitis mimicking brain tumor: Comprehensive analysis of 13 cases from a single institutional cohort of 191 cases. <i>Journal of Autoimmunity</i> , 2019, 97, 22-28.	6.5	20
295	Synovial expression of cell adhesion molecules in polymyalgia rheumatica. <i>Clinical and Experimental Immunology</i> , 1997, 107, 494-500.	2.6	20
296	Dactylitis also involving the synovial sheaths in the palm of the hand: two more cases studied by magnetic resonance imaging. <i>Annals of the Rheumatic Diseases</i> , 1998, 57, 61-62.	0.9	20
297	Magnetic resonance angiography versus 18F-fluorodeoxyglucose positron emission tomography in large vessel vasculitis. <i>Autoimmunity Reviews</i> , 2019, 18, 102405.	5.8	19
298	Predominant ultrasonographic extracapsular changes in symptomatic psoriatic dactylitis: results from a multicenter cross-sectional study comparing symptomatic and asymptomatic hand dactylitis. <i>Clinical Rheumatology</i> , 2020, 39, 1157-1165.	2.2	19
299	COVID-19-associated vasculitis and thrombotic complications: from pathological findings to multidisciplinary discussion. <i>Rheumatology</i> , 2020, 59, e147-e150.	1.9	19
300	The role of interleukin 1, erythropoietin and red cell bound immunoglobulins in the anaemia of rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 1991, 9, 241-6.	0.8	19
301	Follow-Up CT Patterns of Residual Lung Abnormalities in Severe COVID-19 Pneumonia Survivors: A Multicenter Retrospective Study. <i>Tomography</i> , 2022, 8, 1184-1195.	1.8	19
302	Polyarteritis nodosa and HIV infection: No evidence of a direct pathogenic role of HIV. <i>Infection</i> , 1996, 24, 159-161.	4.7	18
303	PLA1/A2 polymorphism of the platelet glycoprotein receptor IIIA and risk of cranial ischemic complications in giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 3502-3508.	6.7	18
304	â€“463 G/A myeloperoxidase promoter polymorphism in giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 485-488.	0.9	18
305	Venous Thromboembolism and Cerebrovascular Events in Patients with Giant Cell Arteritis: A Population-Based Retrospective Cohort Study. <i>PLoS ONE</i> , 2016, 11, e0149579.	2.5	18
306	Ultrasonographic Evidence of Predominance of Acute Extracapsular and Chronic Intrasynovial Patterns in 100 Cases of Psoriatic Hand Dactylitis. <i>Journal of Rheumatology</i> , 2020, 47, 227-233.	2.0	18

#	ARTICLE	IF	CITATIONS
307	Association Between Specimen Length and Number of Sections and Diagnostic Yield of Temporal Artery Biopsy for Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2021, 73, 402-408.	3.4	18
308	Rheumatoid arthritis related interstitial lung disease. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 485-497.	3.0	18
309	Lumbar interspinous bursitis in active polymyalgia rheumatica. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 526-31.	0.8	18
310	Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials. <i>Rheumatology and Therapy</i> , 2022, 9, 521-539.	2.3	18
311	Diagnostic and classification criteria, clinical and functional assessment, and therapeutic advances for spondyloarthropathies. <i>Current Opinion in Rheumatology</i> , 1997, 9, 284-290.	4.3	17
312	Rituximab therapy for primary central nervous system vasculitis: A 6 patient experience and review of the literature. <i>Autoimmunity Reviews</i> , 2019, 18, 399-405.	5.8	17
313	A Candidate Gene Approach Identifies an IL33 Genetic Variant as a Novel Genetic Risk Factor for GCA. <i>PLoS ONE</i> , 2014, 9, e113476.	2.5	17
314	Soluble interleukin 2 receptors in polymyalgia rheumatica/giant cell arteritis. Clinical and laboratory correlations. <i>Journal of Rheumatology</i> , 1992, 19, 1100-6.	2.0	17
315	1T magnetic resonance imaging in the diagnosis of giant cell arteritis: comparison with ultrasonography and physical examination of temporal arteries. <i>Clinical and Experimental Rheumatology</i> , 2008, 26, S76-80.	0.8	17
316	Musculoskeletal manifestations in inflammatory bowel disease. <i>European Journal of Internal Medicine</i> , 2000, 11, 210-214.	2.2	16
317	Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease. <i>Advances in Therapy</i> , 2018, 35, 545-562.	2.9	16
318	Sensing Inflammation Biomarkers with Electrolyte-Gated Organic Electronic Transistors. <i>Advanced Healthcare Materials</i> , 2021, 10, e2100955.	7.6	16
319	Incidence and prevalence of large vessel vasculitis (giant cell arteritis and Takayasu arteritis) in northern Italy: A population-based study. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 786-792.	3.4	16
320	Erythrocyte Sedimentation Rate and C-Reactive Protein in the Diagnosis of Polymyalgia Rheumatica. <i>Annals of Internal Medicine</i> , 1998, 128, 873.	3.9	16
321	Elevated soluble intercellular adhesion molecule 1 in the serum of patients with polymyalgia rheumatica: influence of steroid treatment. <i>Journal of Rheumatology</i> , 1994, 21, 1860-4.	2.0	16
322	Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis involving the central nervous system: case report and review of the literature. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, 759-66.	0.8	16
323	Primary Sjogren's syndrome associated with chronic periaortitis. <i>Rheumatology</i> , 2006, 46, 719-720.	1.9	15
324	Criteria, Frequency, and Duration of Clinical Remission in Psoriatic Arthritis Patients with Peripheral Involvement Requiring Second-line Drugs. <i>Journal of rheumatology Supplement</i> , The, 2009, 83, 78-80.	2.2	15

#	ARTICLE	IF	CITATIONS
325	Evidence-based algorithm for diagnosis and assessment in psoriatic arthritis: results by Italian DELphi in psoriatic Arthritis (IDEA). <i>Reumatismo</i> , 2016, 68, 126-136.	0.9	15
326	Consensus on the management of patients with psoriatic arthritis in a dermatology setting. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 515-528.	2.4	15
327	Polymyalgia rheumatica: an autoinflammatory disorder?. <i>RMD Open</i> , 2018, 4, e000694.	3.8	15
328	Interferon Alpha-2a Treatment for Post-Uveitic Refractory Macular Edema. <i>Ocular Immunology and Inflammation</i> , 2020, 28, 322-328.	1.8	15
329	Use of Neem oil and <i>Hypericum perforatum</i> for treatment of calcinosis-related skin ulcers in systemic sclerosis. <i>Journal of International Medical Research</i> , 2020, 48, 030006051988217.	1.0	15
330	Baricitinib and the Risk of Incident Interstitial Lung Disease: A Descriptive Clinical Case Report from Clinical Trials. <i>Rheumatology and Therapy</i> , 2021, 8, 1435-1441.	2.3	15
331	HLA-DRB1, DQA1, and DQB1 alleles associated with giant cell arteritis in northern Italy. <i>Journal of Rheumatology</i> , 1999, 26, 2395-9.	2.0	15
332	Thrombosis associated with the prothrombin G→A20210 mutation in Behçet's disease. <i>Journal of Rheumatology</i> , 2000, 27, 515-6.	2.0	15
333	Prominent perivascular enhancement in primary central nervous system vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2008, 26, S111.	0.8	15
334	Imaging findings in primary central nervous system vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, S104-9.	0.8	15
335	Chronic Periaortitis. <i>Circulation</i> , 2008, 118, 1214-1216.	1.6	14
336	Predictors of Loss of Remission and Disease Flares in Patients with Axial Spondyloarthritis Receiving Antitumor Necrosis Factor Treatment: A Retrospective Study. <i>Journal of Rheumatology</i> , 2016, 43, 1541-1546.	2.0	14
337	Management of large-vessel vasculitis. <i>Current Opinion in Rheumatology</i> , 2019, 31, 25-31.	4.3	14
338	Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1. <i>Rheumatology and Therapy</i> , 2021, 8, 1789-1808.	2.3	14
339	Epidemiology and management of interstitial lung disease in ANCA-associated vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 221-231.	0.8	14
340	Clinical response to auranofin in patients with psoriatic arthritis. <i>Clinical Rheumatology</i> , 1989, 8, 54-57.	2.2	13
341	Polymyalgia rheumatica and giant cell arteritis. <i>Bailliere's Clinical Rheumatology</i> , 1995, 9, 515-527.	1.0	13
342	Do we need treatment with tumour necrosis factor blockers for giant cell arteritis?. <i>Annals of the Rheumatic Diseases</i> , 2007, 67, 577-579.	0.9	13

#	ARTICLE	IF	CITATIONS
343	Rheumatic Manifestations of Scurvy. <i>Current Rheumatology Reports</i> , 2015, 17, 26.	4.7	13
344	Recent advances in the diagnosis and treatment of polymyalgia rheumatica. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 1037-1045.	3.0	13
345	Multidisciplinary management of patients with coexisting inflammatory bowel disease and spondyloarthritis: A Delphi consensus among Italian experts. <i>Digestive and Liver Disease</i> , 2017, 49, 1298-1305.	0.9	13
346	Contribution of the new 2012 EULAR/ACR classification criteria for the diagnosis of polymyalgia rheumatica. <i>Reumatismo</i> , 2018, 70, 18-22.	0.9	13
347	New perspectives in eosinophilic granulomatosis with polyangiitis (EGPA): report of the first meeting of the European EGPA Study Group. <i>Internal and Emergency Medicine</i> , 2019, 14, 1193-1197.	2.0	13
348	⁶⁴ Cu and fluorescein labeled anti-miRNA peptide nucleic acids for the detection of miRNA expression in living cells. <i>Scientific Reports</i> , 2019, 9, 3376.	3.3	13
349	Interferon Alpha-2a for the Treatment of Post-Infectious Uveitis Secondary to Presumed Intraocular Tuberculosis. <i>Ocular Immunology and Inflammation</i> , 2019, 27, 643-650.	1.8	13
350	Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy. <i>Rheumatology</i> , 2021, 60, S125-S136.	1.9	13
351	An Italian shared dermatological and rheumatological proposal for the use of biological agents in psoriatic disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 578-586.	2.4	12
352	CC chemokine receptor 5 polymorphism in Italian patients with Behcet's disease. <i>Rheumatology</i> , 2012, 51, 2141-2145.	1.9	12
353	The Role of Tumor Necrosis Factor- α Blockers in Psoriatic Disease. <i>Therapeutic Options in Psoriatic Arthritis. Journal of rheumatology Supplement, The</i> , 2015, 93, 73-78.	2.2	12
354	Impact of training on concordance among rheumatologists and dermatologists in the assessment of patients with psoriasis and psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 305-311.	3.4	12
355	Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis: An Italian Real-Life Retrospective Study. <i>Frontiers in Pharmacology</i> , 2019, 10, 1497.	3.5	12
356	Interstitial Pneumonia with Autoimmune Features: Why Rheumatologist-Pulmonologist Collaboration Is Essential. <i>Biomedicines</i> , 2021, 9, 17.	3.2	12
357	Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology. <i>Journal of Rheumatology</i> , 2022, 49, 176-185.	2.0	12
358	Serum soluble CD4 and CD8 levels in polymyalgia rheumatica. <i>Journal of Rheumatology</i> , 1994, 21, 1865-9.	2.0	12
359	Anticardiolipin antibodies in northern italian population with PMR/GCA. <i>American Journal of Medicine</i> , 1992, 92, 712-713.	1.5	11
360	Primary central nervous system vasculitis: Is it a single disease?. <i>Annals of Neurology</i> , 2010, 68, 573-574.	5.3	11

#	ARTICLE	IF	CITATIONS
361	G/R 241 Polymorphism of Intercellular Adhesion Molecule 1 (<i>ICAM-1</i>) Is Associated with Fuchs Uveitis. , 2010, 51, 4447.		11
362	Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNF± drugs. <i>Reumatismo</i> , 2014, 66, 208-214.	0.9	11
363	Effectiveness of Infliximab and Interferon Alpha-2a for the Treatment of Behçet's Uveitis: Customizing Therapy according to the Clinical Features. <i>Ocular Immunology and Inflammation</i> , 2022, 30, 506-514.	1.8	11
364	Improvement of Function and Its Determinants in a Group of Axial Spondyloarthritis Patients Treated with TNF Inhibitors: A Real-Life Study. <i>Rheumatology and Therapy</i> , 2020, 7, 301-310.	2.3	11
365	Systemic sclerosis cutaneous expression: Management of skin fibrosis and digital ulcers. <i>Annals of Medicine and Surgery</i> , 2021, 71, 102984.	1.1	11
366	VECTOR: An algorithm for the detection of COVID-19 pneumonia from velcro-like lung sounds. <i>Computers in Biology and Medicine</i> , 2022, 142, 105220.	7.0	11
367	Recommendations of the Italian Society for Rheumatology for the use of biologic (TNF-alpha blocking) agents in the treatment of psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2006, 24, 70-8.	0.8	11
368	Toll-like receptor 4 (TLR4) gene polymorphisms in Italian patients with Behçet's disease. <i>Clinical and Experimental Rheumatology</i> , 2009, 27, S43-7.	0.8	11
369	Adalimumab in Psoriatic Arthritis. <i>Journal of rheumatology Supplement, The</i> , 2012, 89, 77-81.	2.2	10
370	Clinical images: PET-CT and contrast-enhanced ultrasound in Takayasu's arteritis. <i>Rheumatology</i> , 2014, 53, 447-447.	1.9	10
371	Usefulness of PET in recognizing and managing vasculitides. <i>Current Opinion in Rheumatology</i> , 2018, 30, 24-29.	4.3	10
372	Physician's Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study. <i>Journal of Rheumatology</i> , 2018, 45, 1256-1262.	2.0	10
373	Pathogenesis and treatment of idiopathic and rheumatoid arthritis-related interstitial pneumonia. The possible lesson from COVID-19 pneumonia. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 751-770.	3.0	10
374	Effectiveness of steroid injection for hand psoriatic dactylitis: results from a multicentre prospective observational study. <i>Clinical Rheumatology</i> , 2020, 39, 3383-3392.	2.2	10
375	Efficacy and safety of rituximab in the treatment of connective tissue disease-related interstitial lung disease. <i>Drugs in Context</i> , 2021, 10, 1-12.	2.2	10
376	Geographical and genetic factors do not account for significant differences in the clinical spectrum of giant cell arteritis in southern europe. <i>Journal of Rheumatology</i> , 2004, 31, 520-3.	2.0	10
377	Radiologist-rheumatologist multidisciplinary approach in the management of axial spondyloarthritis: a Delphi consensus statement. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 575-584.	0.8	10
378	Hypothyroidism Simulating Polymyositis. <i>Scandinavian Journal of Rheumatology</i> , 1988, 17, 147-149.	1.1	9

#	ARTICLE	IF	CITATIONS
379	Giant cell arteritis in Mediterranean countries: Comment on the article by Salvarani et al. <i>Arthritis and Rheumatism</i> , 1992, 35, 1249-1250.	6.7	9
380	RS3PE: six years later. <i>Annals of the Rheumatic Diseases</i> , 1999, 58, 722-723.	0.9	9
381	Whole exome sequencing identifies rare protein-coding variants in Behçet's disease. <i>Arthritis and Rheumatology</i> , 2015, 68, n/a-n/a.	5.6	9
382	Frequency of monoclonal gammopathy in psoriatic patients receiving anti-TNF therapy compared with patients taking conventional drugs: a cross-sectional study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 2262-2263.	2.4	9
383	TOCID-19 - A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocol. <i>Contemporary Clinical Trials</i> , 2020, 98, 106165.	1.8	9
384	The Italian Society of Rheumatology clinical practice guidelines for the management of polymyalgia rheumatica. <i>Reumatismo</i> , 2020, 72, 1-15.	0.9	9
385	Combination Therapy with Nintedanib and Sarilumab for the Management of Rheumatoid Arthritis Related Interstitial Lung Disease. <i>Case Reports in Medicine</i> , 2020, 2020, 1-4.	0.7	9
386	Efficacy and Drug Survival after Switching from Etanercept to the Biosimilar SB4: A Real-Life Long-Term Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 621.	2.4	9
387	Toll-like receptor 4 (TLR4) gene polymorphisms in giant cell arteritis. <i>Clinical and Experimental Rheumatology</i> , 2009, 27, S40-4.	0.8	9
388	Mortality Prediction of COVID-19 Patients Using Radiomic and Neural Network Features Extracted from a Wide Chest X-ray Sample Size: A Robust Approach for Different Medical Imbalanced Scenarios. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 3903.	2.5	9
389	Isolated knee monoarthritis heralding resectable non-small-cell lung cancer. A paraneoplastic syndrome not previously described. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1672-1674.	0.9	8
390	TLR-4 and VEGF Polymorphisms in Chronic Periaortitis. <i>PLoS ONE</i> , 2013, 8, e62330.	2.5	8
391	Colonic perforation due to severe cytomegalovirus disease in granulomatosis with polyangiitis after immunosuppression. <i>Clinical Rheumatology</i> , 2018, 37, 1427-1432.	2.2	8
392	CD3 immunohistochemistry is helpful in the diagnosis of giant cell arteritis. <i>Rheumatology</i> , 2018, 57, 1377-1380.	1.9	8
393	Imaging in polymyalgia rheumatica. <i>Reumatismo</i> , 2018, 70, 51-58.	0.9	8
394	Ultrasonographic and clinical assessment of peripheral enthesitis and arthritis in an Italian cohort of inflammatory bowel disease patients. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 436-443.	3.4	8
395	Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: a narrative review. <i>Drugs in Context</i> , 2021, 10, 1-17.	2.2	8
396	Interstitial Lung Disease and Anti-Myeloperoxidase Antibodies: Not a Simple Association. <i>Journal of Clinical Medicine</i> , 2021, 10, 2548.	2.4	8

#	ARTICLE	IF	CITATIONS
397	New insights into the pathogenesis of giant cell arteritis: are they relevant for precision medicine?. <i>Lancet Rheumatology</i> , The, 2021, 3, e874-e885.	3.9	8
398	Elevated serum concentrations of the chemokine RANTES in patients with polymyalgia rheumatica. <i>Clinical and Experimental Rheumatology</i> , 1998, 16, 263-8.	0.8	8
399	Absence of the association with CC chemokine receptor 5 polymorphism in polymyalgia rheumatica. <i>Clinical and Experimental Rheumatology</i> , 2000, 18, 591-5.	0.8	8
400	Catastrophic primary central nervous system vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2014, 32, S3-4.	0.8	8
401	Photobiomodulation Therapy: A New Light in the Treatment of Systemic Sclerosis Skin Ulcers. <i>Rheumatology and Therapy</i> , 2022, 9, 891-905.	2.3	8
402	New indications for biological therapies. <i>Internal and Emergency Medicine</i> , 2011, 6, 1-9.	2.0	7
403	[18F]fluorodeoxyglucose positron emission tomography imaging in a case of relapsing polychondritis. <i>Rheumatology</i> , 2012, 51, 1813-1813.	1.9	7
404	The INTERNational Study on Primary Angiitis of the CEntral Nervous System "A Call to the World. <i>International Journal of Stroke</i> , 2014, 9, E23-E23.	5.9	7
405	Standardization of red flags for referral to rheumatologists and ophthalmologists in patients with rheumatic diseases and ocular involvement: a consensus statement. <i>Rheumatology International</i> , 2018, 38, 1727-1734.	3.0	7
406	The therapeutic potential of tuftsin-phosphorylcholine in giant cell arteritis. <i>Journal of Autoimmunity</i> , 2019, 98, 113-121.	6.5	7
407	Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network. <i>Mediators of Inflammation</i> , 2020, 2020, 1-6.	3.0	7
408	Vessel inflammation and morphological changes in patients with large vessel vasculitis: a retrospective study. <i>RMD Open</i> , 2022, 8, e001977.	3.8	7
409	Interstitial lung disease in Sjögren's syndrome: a clinical review. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 291-300.	0.8	7
410	Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210903.	2.7	7
411	Comparing treatment options for large vessel vasculitis. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 793-805.	3.0	7
412	Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies. <i>Current Pharmaceutical Design</i> , 2022, 28, 2022-2028.	1.9	7
413	Anticardiolipin antibodies in a case of neuro-Behçet with superior vena caval occlusion. <i>Clinical Rheumatology</i> , 1987, 6, 88-91.	2.2	6
414	Golimumab: A Novel Anti-Tumor Necrosis Factor. <i>Biologics in Therapy</i> , 2013, 3, 83-107.	1.8	6

#	ARTICLE	IF	CITATIONS
415	IgG4-Related Sacroiliitis. <i>Arthritis and Rheumatology</i> , 2016, 68, 774-774.	5.6	6
416	Efficacy of Rituximab Treatment in Vogt-Koyanagi-Harada Disease Poorly Controlled by Traditional Immunosuppressive Treatment. <i>Ocular Immunology and Inflammation</i> , 2021, , 1-6.	1.8	6
417	Musculoskeletal Ultrasound in Monitoring Clinical Response to Treatment in Acute Symptomatic Psoriatic Dactylitis: Results from a Multicentre Prospective Observational Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3127.	2.4	6
418	Synovitis in polymyalgia rheumatica: a 5-year followup study in Reggio Emilia, Italy. <i>Journal of Rheumatology</i> , 1987, 14, 1209-10.	2.0	6
419	Recommendations of the Italian Society of Rheumatology for the treatment of the primary large-vessel vasculitis with biological agents. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S139-61.	0.8	6
420	Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, S86-92.	0.8	6
421	An observational prospective study on predictors of clinical response at six months in patients with active psoriatic arthritis treated with golimumab. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 107-114.	0.8	6
422	Empowering Patients in the Therapeutic Decision-Making Process: A Glance Into Behçet's Syndrome. <i>Frontiers in Medicine</i> , 2021, 8, 769870.	2.6	6
423	Arterial Stiffness and Adult Onset Vasculitis: A Systematic Review. <i>Frontiers in Medicine</i> , 2022, 9, .	2.6	6
424	Nephrotic syndrome induced by tiopronin: Association with the HLA-DR3 antigen. <i>Arthritis and Rheumatism</i> , 1985, 28, 595-596.	6.7	5
425	Thalidomide, deep venous thrombosis and vasculitis. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 2062-2063.	3.8	5
426	Lack of association of the 463 G/A myeloperoxidase promoter polymorphism with Behçet's disease in Italian patients. <i>Rheumatology</i> , 2007, 46, 1547-1550.	1.9	5
427	Multidisciplinary Focus on Cyclosporin A. <i>Journal of rheumatology Supplement, The</i> , 2009, 83, 52-55.	2.2	5
428	Biologics in vasculitides: Where do we stand, where do we go from now?. <i>Presse Medicale</i> , 2015, 44, e231-e239.	1.9	5
429	Biotherapies in large vessel vasculitis. <i>Revue De Medecine Interne</i> , 2016, 37, 274-278.	1.0	5
430	Cardiac involvement in the adult primary vasculitides. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 985-991.	3.0	5
431	Citelman syndrome associated with chondrocalcinosis and severe neuropathy: a novel heterozygous mutation in SLC12A3 gene. <i>Reumatismo</i> , 2020, 72, 67-70.	0.9	5
432	Autologous fat grafting in the treatment of a scleroderma stump-skin ulcer: a case report. <i>Case Reports in Plastic Surgery & Hand Surgery</i> , 2021, 8, 18-22.	0.3	5

#	ARTICLE	IF	CITATIONS
433	Sensitivity to change and clinical correlations of the novel DACTylitis glObal Sonographic (DACTOS) score in psoriatic arthritis. <i>Rheumatology</i> , 2021, 60, 4103-4111.	1.9	5
434	Usefulness of Digital Velcro Crackles Detection in Identification of Interstitial Lung Disease in Patients With Connective Tissue Diseases. <i>Archives of Rheumatology</i> , 2021, 36, 19-25.	0.9	5
435	On the utility of CD8 level assessment in the diagnosis of polymyalgia rheumatica/giant cell arteritis. <i>Clinical and Experimental Rheumatology</i> , 1995, 13, 129-30.	0.8	5
436	Giant-cell arteritis of the female genital tract associated with occult temporal arteritis and FDG-PET evidence of large-vessel vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2007, 25, S36-9.	0.8	5
437	Cyclosporine in psoriatic arthropathy. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S101-3.	0.8	5
438	High-dose glucocorticoids pulse-therapy for beta-coronaviridae pneumonia: a systematic literature review and case-series of Coronavirus disease-2019. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 1119-1125.	0.8	5
439	Inflammatory burden and persistent CT lung abnormalities in COVID-19 patients. <i>Scientific Reports</i> , 2022, 12, 4270.	3.3	5
440	Synovitis in Polymyalgia Rheumatica: An Immunogenetic Study. <i>Rheumatology</i> , 1992, 31, 720-720.	1.9	4
441	Retrocalcaneal bursitis in polymyalgia rheumatica. <i>Annals of the Rheumatic Diseases</i> , 2001, 60, 1160-1161.	0.9	4
442	Functional Progression in Patients with Interstitial Lung Disease Resulted Positive to Antisynthetase Antibodies: A Multicenter, Retrospective Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 3033.	2.4	4
443	Pirfenidone for the treatment of interstitial lung disease associated to rheumatoid arthritis: a new scenario is coming?. <i>Respiratory Medicine Case Reports</i> , 2020, 30, 101051.	0.4	4
444	Management of Systemic Sclerosis Patients in the COVID-19 Era: The Experience of an Expert Specialist Reference Center. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , 2021, 15, 117954842110013.	0.9	4
445	Cataract Surgery with Intraocular Lens Implantation in Juvenile Idiopathic Arthritis-Associated Uveitis: Outcomes in the Era of Biological Therapy. <i>Journal of Clinical Medicine</i> , 2021, 10, 2437.	2.4	4
446	Adult Primary Central Nervous System Vasculitis. , 2016, , 245-257.		4
447	Use of Ultrasonography to Discriminate Psoriatic Arthritis from Fibromyalgia: A Post-Hoc Analysis of the ULISSE Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 180.	2.4	4
448	Could different aqueous humor and plasma cytokine profiles help differentiate between ocular sarcoidosis and ocular tuberculosis?. <i>Inflammation Research</i> , 2022, 71, 949-961.	4.0	4
449	Synovial expression of cell adhesion molecules in polymyalgia rheumatica. <i>Clinical and Experimental Immunology</i> , 2009, 107, 494-500.	2.6	3
450	Diagnosis and Management of Polymyalgia Rheumatica/Giant Cell Arteritis. <i>BioDrugs</i> , 1998, 9, 25-32.	4.6	3

#	ARTICLE	IF	CITATIONS
451	Systemic vasculitis: state of the art and emerging concepts. <i>Current Opinion in Rheumatology</i> , 2006, 18, 1-2.	4.3	3
452	Comment on: Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis: reply. <i>Rheumatology</i> , 2009, 48, 1180-1180.	1.9	3
453	CC chemokine receptor 5 polymorphism in Italian patients with giant cell arteritis. <i>Modern Rheumatology</i> , 2013, 23, 851-855.	1.8	3
454	Do we need FDG-PET/CT to assess atherosclerosis?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 247-248.	6.4	3
455	Nailfold videocapillaroscopy in antisynthetase syndrome. <i>Reumatismo</i> , 2018, 70, 257-258.	0.9	3
456	Clinical Relevance of Subcentimetric Lymph Node Biopsy in the Diagnosis of Ocular Sarcoidosis. <i>Ocular Immunology and Inflammation</i> , 2022, 30, 717-720.	1.8	3
457	Reading and interpreting reviews for health professionals: a practical review. <i>Internal and Emergency Medicine</i> , 2020, 15, 945-955.	2.0	3
458	AB0522â€¦SAFETY PROFILE OF UPADACITINIB UP TO 3 YEARS IN PATIENTS WITH PSORIATIC ARTHRITIS: AN INTEGRATED ANALYSIS FROM THE PHASE 3 PROGRAM. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1287-1288.	0.9	3
459	Survival and Recurrence in Vitreoretinal Lymphoma Simulating Uveitis at Presentation: The Possible Role of Combined Chemotherapy. <i>Ocular Immunology and Inflammation</i> , 2021, , 1-9.	1.8	3
460	Ultrasound Effectiveness of Steroid Injection for hand Psoriatic Dactylitis: Results from a Longitudinal Observational Study. <i>Rheumatology and Therapy</i> , 2021, 8, 1809-1826.	2.3	3
461	Clinical Features and Prevalence of Spondyloarthritis in a Cohort of Italian Patients Presenting with Acute Nongranulomatous Anterior Uveitis. <i>Journal of Immunology Research</i> , 2022, 2022, 1-9.	2.2	3
462	Immunologic effects in patients with psoriatic arthritis treated with cyclosporine A. <i>Journal of Rheumatology</i> , 1992, 19, 1933-7.	2.0	3
463	Long-term outcome of giant cell arteritis. <i>Clinical and Experimental Rheumatology</i> , 2006, 24, S65-70.	0.8	3
464	Imbalance between angiogenic and anti-angiogenic factors in sera from patients with large-vessel vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 23-30.	0.8	3
465	Association between Leeds Dactylitis Index and ultrasonographic features: a multicentre study on psoriatic hand dactylitis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1112-1117.	0.8	3
466	Acute-phase reactants during tocilizumab therapy for severe COVID-19 pneumonia. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1215-1222.	0.8	3
467	Apremilast retention rate in clinical practice: observations from an Italian multi-center study. <i>Clinical Rheumatology</i> , 2022, 41, 3219-3225.	2.2	3
468	Comment on: Longitudinal examination with shoulder ultrasound in patients with polymyalgia rheumatica: reply. <i>Rheumatology</i> , 2010, 49, 1998-1999.	1.9	2

#	ARTICLE	IF	CITATIONS
469	Recommendations for the appropriate use of anti-TNF \pm therapy in patients with psoriatic arthritis. Reumatismo, 2011, 56, .	0.9	2
470	L30. Assessment of vasculitis extent and severity. Presse Medicale, 2013, 42, 588-589.	1.9	2
471	Is 18F Fluorodeoxyglucose Positron Emission Tomography Useful to Assess Activity of Myositis?. Journal of Rheumatology, 2013, 40, 91.2-91.	2.0	2
472	Therapeutic Options After Treatment Failure in Rheumatoid Arthritis or Spondyloarthritides. Advances in Therapy, 2014, 31, 780-802.	2.9	2
473	Response to: 'Artery tertiary lymphoid organs in giant cell arteritis are not exclusively located in the media of temporal arteries' by Graver et al. Annals of the Rheumatic Diseases, 2018, 77, e17-e17.	0.9	2
474	Cardiac and Pulmonary Artery Involvement Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Large-vessel Giant Cell Arteritis. Journal of Rheumatology, 2018, 45, 1603-1604.	2.0	2
475	Long-term Outcome of Children Born to Women with Autoimmune Rheumatic Diseases: A Multicentre, Nationwide Study on 299 Randomly Selected Individuals. Clinical Reviews in Allergy and Immunology, 2022, 62, 346-353.	6.5	2
476	CC chemokine receptor 5 polymorphism in Italian patients with giant cell arteritis. Modern Rheumatology, 2013, 23, 851-855.	1.8	2
477	Initiative for quality in psoriasis and psoriatic arthritis. Journal of Rheumatology, 2008, 35, 1431-3.	2.0	2
478	Adalimumab and ABP 501 in the Treatment of a Large Cohort of Patients with Inflammatory Arthritis: A Real Life Retrospective Analysis. Journal of Personalized Medicine, 2022, 12, 335.	2.5	2
479	Possibile mixoma endoventricolare sinistro in paziente con TVP degli arti inferiori: considerazioni da un caso clinico. Italian Journal of Medicine, 2011, 5, 184-189.	0.3	1
480	Large-Vessel Vasculitis. , 2019, , 609-618.		1
481	FRI0284...RESULTS OF A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS: EVIDENCE TO GUIDE THE MANAGEMENT OF GIANT CELL ARTERITIS. , 2019, , .		1
482	Vasculitis in a patient with mixed cryoglobulinemia treated with rituximab biosimilar CT-P10: a case report. Modern Rheumatology Case Reports, 2020, 4, 102-105.	0.7	1
483	Invited Response on: Comments on 'Autologous Fat Grafting for the Oral and Digital Complications of Systemic Sclerosis: Results of a Prospective Study' Aesthetic Plastic Surgery, 2021, 45, 1344-1345.	0.9	1
484	Comments on: 'Unexpected detection of SARS-CoV-2 antibodies in the pre-pandemic period in Italy' Tumori, 2021, 107, 030089162199243.	1.1	1
485	18F-FDG PET-CT versus contrast enhanced CT for the diagnosis of fever of unknown origin. European Journal of Internal Medicine, 2021, 93, 26-27.	2.2	1
486	Response to 'The Relevance of Restricted Inflammation in a TAB β ' by Griffin KJ et al.. Seminars in Arthritis and Rheumatism, 2021, 51, e8-e9.	3.4	1

#	ARTICLE	IF	CITATIONS
487	Polyarteritis Nodosa. , 2016, , 189-196.		1
488	THU0600â€¦A CASE OF SYSTEMIC SCLEROSIS COMPLICATED BY RENAL CRISIS: POTENTIAL ETIOPATHOGENETIC ROLE OF CYTOMEGALOVIRUS AND TREATMENT. Annals of the Rheumatic Diseases, 2020, 79, 542.1-542.	0.9	1
489	Epidemiology of Behçet Syndrome. Rare Diseases of the Immune System, 2014, , 17-24.	0.1	1
490	AB0039â€¦ROLE OF MESENCHYMAL STEM CELLS ISOLATED FROM DENTAL PULP (DPSCS) IN IMMUNOREGULATION PROCESSES MEDIATED BY PROGRAMMED DEATH-LIGAND 1 (PD-L1). Annals of the Rheumatic Diseases, 2020, 79, 1322.1-1322.	0.9	1
491	Scurvy mimicking spondyloarthritis in a young man. Clinical and Experimental Rheumatology, 2013, 31, 795.	0.8	1
492	Comparison of biopsy-proven giant cell arteritis in North America and Southern Europe: a population-based study. Clinical and Experimental Rheumatology, 2020, 38 Suppl 124, 79-83.	0.8	1
493	Failure of first anti-TNF agent in Takayasu's arteritis: to switch or to swap?. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 129-134.	0.8	1
494	Interstitial lung disease in ANCA-associated vasculitis: another step forward. Clinical and Experimental Rheumatology, 2021, 39, 193-193.	0.8	1
495	This letter was shown to Dr. Macchioni et al. who reply. Rheumatology, 1994, 33, 195-195.	1.9	0
496	Giant cell arteritis and amyloidosis: comment on the article by Salvarani et al. Arthritis and Rheumatism, 1996, 39, 1073-1074.	6.7	0
497	Cardiac Involvement in Systemic Vasculitis. Handbook of Systemic Autoimmune Diseases, 2003, 1, 227-254.	0.1	0
498	Chronic Periaortitis (CP). Medical Radiology, 2011, , 175-185.	0.1	0
499	CLINICAL ASSESSMENT IN PSORIATIC ARTHRITIS. Reumatismo, 2011, 59, 68-72.	0.9	0
500	Comparison of CNS vasculitis in children and adults; is this the same disease entity. Pediatric Rheumatology, 2011, 9, .	2.1	0
501	Aortite et pŕiaortite dans la spondylarthrite ankylosante. Revue Du Rhumatisme (Edition Francaise), 2011, 78, 227-231.	0.0	0
502	Myocardial Positron Emission Tomography/Computed Tomography Scan Revealing Right Coronary Artery Involvement in Large Vessel Vasculitis. Journal of Rheumatology, 2012, 39, 1761.2-1763.	2.0	0
503	Comparison of CNS vasculitis in children and adults; is this the same disease entity. Pediatric Rheumatology, 2012, 10, .	2.1	0
504	Possible left endoventricular myxoma in a patient with deep vein thrombosis of the lower limbs: a case report. Italian Journal of Medicine, 2013, , 184-189.	0.3	0

#	ARTICLE	IF	CITATIONS
505	Ignazio Olivieri, MD, 1953â€“2017. Journal of Rheumatology, 2017, 44, 1682-1682.	2.0	0
506	Behçetâ€™s Disease. , 2017, , 505-526.		0
507	FRI0613â€…THERAPEUTIC STRATEGIES AND SURVIVAL IN PATIENTS WITH INTERSTITIAL PNEUMONIA WITH AUTOIMMUNE FEATURES. , 2019, , .		0
508	AB0212â€…LONG-TERM TREATMENT WITH RITUXIMAB IN SYSTEMIC SCLEROSISMANAGEMENT: AN OVERVIEW OF THE CLINICAL EXPERIENCE FROM A REAL-LIFE SETTING. , 2019, , .		0
509	THU0349â€…AUTOLOGOUS FAT GRAFTING IN THE TREATMENT OF PATIENTS WITH SYSTEMIC SCLEROSIS: CURRENT EXPERIENCE AND FUTURE PROSPECTS. , 2019, , .		0
510	Chronic periaortitis presenting with isolated pulmonary artery involvement: description of two cases. Rheumatology, 2021, 60, e285-e287.	1.9	0
511	The management of large vessel vasculitides. Beyond Rheumatology, 2021, 3, .	0.3	0
512	AB0425â€…CLINICAL AND PATHOLOGICAL FEATURES OF BREAST CANCER IN PATIENTS WITH SYSTEMIC SCLEROSIS: PRELIMINARY DATA FROM THE SCLERO-BREAST STUDY. Annals of the Rheumatic Diseases, 2021, 80, 1241.1-1241.	0.9	0
513	OP0310â€…GENDER AND FIBROMYALGIA SEVERITY: REAL LIFE DATA FROM THE ITALIAN REGISTRY. Annals of the Rheumatic Diseases, 2021, 80, 190-191.	0.9	0
514	POS0837â€…THE USE OF CANNABIDIOL IN THE TREATMENT OF PAIN RELATED TO SCLERODERMA DIGITAL ULCERS. Annals of the Rheumatic Diseases, 2021, 80, 672.2-673.	0.9	0
515	POS0927â€…EFFECTIVENESS AND SAFETY OF SECUKINUMAB IN NAÏVE OR TNF-INHIBITORS FAILURE AXIAL SPONDYLOARTHRITIS PATIENTS IN REAL LIFE: A 24-MONTHS PROSPECTIVE MULTICENTRIC STUDY. Annals of the Rheumatic Diseases, 2021, 80, 726.1-726.	0.9	0
516	AB0716â€…FIBROMYALGIA SYNDROME SEVERITY ACCORDING TO AGE CATEGORIES: RESULTS FROM A NATIONAL REGISTER. Annals of the Rheumatic Diseases, 2021, 80, 1389.2-1390.	0.9	0
517	Skin Manifestations in Giant Cell Arteritis. , 2014, , 337-342.		0
518	Skin Manifestations in Microscopic Polyangiitis. , 2014, , 313-319.		0
519	Coganâ€™s Syndrome. , 2016, , 749-754.		0
520	FRI0504â€…Diffuse alveolar haemorrhagein anca-associated vasculitis: can we predict outcome? an italian multicentre retrospective long-term study of 102 patients. , 2018, , .		0
521	AB0760â€…Advanced oxidation protein products in serum of patients with systemic sclerosis: a possible indicator of clinical evolution. , 2018, , .		0
522	FRI0212â€…THE ROLE OF AGE ON THE CLINICAL PRESENTATION AND RELAPSE RATES IN A LARGE COHORT OF 720 PATIENTS WITH GIANT CELL ARTERITIS. Annals of the Rheumatic Diseases, 2020, 79, 689.1-690.	0.9	0

#	ARTICLE	IF	CITATIONS
523	THU0298â€¦SWITCH OR SWAP STRATEGY IN TAKAYASU ARTERITIS PATIENTS FAILING TNFA INHIBITORS?. Annals of the Rheumatic Diseases, 2020, 79, 377-377.	0.9	0
524	Interleukin-6 expression in inflamed and non-inflamed temporal arteries from patients with giant cell arteritis. Clinical and Experimental Rheumatology, 2019, 37 Suppl 117, 98-103.	0.8	0
525	Enthesitis and small cell lung carcinoma: a novel paraneoplastic syndrome not previously described. Clinical and Experimental Rheumatology, 2020, 38, 372.	0.8	0
526	Methylprednisolone as rescue therapy after tocilizumab failure in patients with severe COVID-19 pneumonia. Clinical and Experimental Rheumatology, 2021, 39, 1141.	0.8	0
527	Interstitial lung disease in ANCA-associated vasculitis: another step forward. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 193.	0.8	0
528	Reply to the comment on: Hypereosinophilic bronchiolitis in ANCA-associated vasculitis: where does it stand? by Bilgin et al. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 197.	0.8	0
529	Reply to the comment on: Hypereosinophilic bronchiolitis in ANCA-associated vasculitis: where does it stand? by Bilgin et al.. Clinical and Experimental Rheumatology, 2021, 39, 197-197.	0.8	0
530	Vasculitis, fibromuscular dysplasia or hereditary aneurysms?. Clinical and Experimental Rheumatology, 2022, , .	0.8	0